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Abstract: The introduction of immune checkpoint inhibitors (ICI), as a novel treatment modality,
has transformed the field of oncology with unprecedented successes. However, the efficacy of ICI for
patients with glioblastoma or brain metastases (BMs) from any tumor type is under debate. Therefore,
we systematically reviewed current literature on the use of ICI in patients with glioblastoma and
BMs. Prospective and retrospective studies evaluating the efficacy and survival outcomes of ICI in
patients with glioblastoma or BMs, and published between 2006 and November 2019, were considered.
A total of 88 studies were identified (n = 8 in glioblastoma and n = 80 in BMs). In glioblastoma,
median progression-free (PFS) and overall survival (OS) of all studies were 2.1 and 7.3 months,
respectively. In patients with BMs, intracranial responses have been reported in studies with
melanoma and non-small-cell lung cancer (NSCLC). The median intracranial and total PFS in these
studies were 2.7 and 3.0 months, respectively. The median OS in all studies for patients with brain
BMs was 8.0 months. To date, ICI demonstrate limited efficacy in patients with glioblastoma or
BMs. Future research should focus on increasing the local and systemic immunological responses in
these patients.
Keywords: Immune checkpoint inhibitors; glioblastoma; brain metastases; brain tumor;
systematic review
1. Introduction
Treating patients with primary brain tumors and brain metastases can be challenging. This is
primarily due to the poor prognosis of these patients despite maximal treatment and the presence of the
blood–brain barrier, posing an obstacle to overcome for most systemic treatments [1]. Glioblastoma is
the most common and most aggressive primary brain tumor in adults, accounting for more than 50% of
all gliomas. Currently, first-line standard treatment for patients with glioblastoma consists of maximal
Cancers 2020, 12, 586; doi:10.3390/cancers12030586 www.mdpi.com/journal/cancers
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resection, followed by postoperative radiotherapy (RT) with concomitant and adjuvant temozolomide
(TMZ) chemotherapy [2]. Since the addition of TMZ to postoperative treatment, two-year and five-year
survival have improved to 27% and 10%, respectively [3]. Furthermore, the addition of tumor-treating
fields, an anti-mitotic treatment modality, to TMZ maintenance therapy demonstrated a statistically
significant improvement in progression-free and overall survival, compared to TMZ maintenance
therapy alone (6.7 months vs. 4.0 months and 20.9 months vs. 16.0 months, respectively) [4]. However,
recurrence is almost inevitable and therefore, the prognosis for these patients remains poor with a
median survival of only 12–15 months [3]. At the time of recurrence, options are limited due to
the distinct limitations in the use of surgery and re-irradiation, and the poor treatment response to
chemotherapy and targeted therapy [5–7].
Brain metastases (BMs) occur in 8–10% of all cancer patients as an unfortunate complication of
systemic dissemination [8,9]. The cumulative incidence of brain metastases is highest in melanoma
(28%), followed by lung cancer (27%), renal cell cancer (11%), breast cancer (8%), and testicular
cancer (8%) [10]. Similar to glioblastoma, most patients with brain metastases have a dismal
prognosis of 12–15 months despite multidisciplinary treatment with surgery, irradiation and/or
systemic treatment [11]. Therefore, there is an unmet need for more effective treatments for patients
with glioblastoma or brain metastases.
Over the past few decades, significant progress has been made in the understanding of how
cancer cells are able to evade the immune system through the expression of immune checkpoints that
suppress T cell function and proliferation. Currently, the clinically most relevant immune checkpoints
are the cytotoxic T lymphocyte antigen 4 (CTLA-4), the programmed death 1 receptor (PD-1) and its
ligand (PD-L1) [12,13]. Interestingly, blockade of these immune checkpoints with antibodies, such as
ipilimumab (anti-CTLA-4), nivolumab (anti-PD-1), and pembrolizumab (anti-PD-1), successfully
demonstrated efficacy in various solid tumors, predominantly melanoma and non-small cell lung
cancer (NSCLC), and prolonged the survival of patients with extracranial disease [14–16].
The introduction of immune checkpoint inhibitors (ICI), as an unprecedented treatment modality,
has consequences for clinical decision making of neuro-oncologists and treatment recommendations of
Neuro-Oncology tumor boards. Furthermore, these treatment recommendations and decisions
may differ per tumor type. Therefore, we systematically reviewed and summarized current
literature on the use of checkpoint inhibitors in patients with glioblastoma and brain metastases




The systematic review followed the guidelines of the Preferred Reporting Items for Systematic
Reviews and Meta-Analysis (PRISMA)-statement (http://www.prisma-statement.org). PubMed,
EMBASE.com and the Cochrane Library (via Wiley) were searched for potentially eligible publications
from inception (by C.B. and R.O.) up to 11 November 2019. The following keywords (including
synonyms and closely related words) were used as index terms or free-text words: ‘glioblastoma OR
gbm’ or ‘brain metastases OR central nervous system metastases’ and ‘immunotherapy OR immune
checkpoint inhibitor’. A full overview of the complete search strategies can be found in supplementary
Table S1. Subsequently, the titles and abstracts found by the database searches were exported to a
reference manager database to remove all duplicate articles.
2.2. Study Selection
Eligible studies included (i) prospective or retrospective studies in patients with glioblastoma or
brain metastases, (ii) reporting on the efficacy and survival outcomes after treatment with immune
checkpoint inhibitors and (iii) were published in English between January 2006 and the end of
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November 2019. Case reports, scientific abstracts or studies with <10 patients were excluded. In the
first selection phase, two authors (C.B. and M.L.) independently screened and reviewed the titles and
abstracts of all identified articles.
2.3. Data Extraction and Statistical Analysis
The two reviewers (C.B. and M.L.) extracted the following data from each article: author (year),
study design, tumor type, therapeutic agent and dose, type of radiation therapy, number of participants,
objective response rate (ORR), local brain metastasis control rate at 6 and 12 months, distant brain
metastasis control rate at 6 and 12 months, progression-free survival (PFS), and overall survival (OS).
If criteria other than RANO or RECIST were used, these were taken into consideration for calculating
the ORR. In case ORR was not reported in an article, it was calculated from raw proportions of events
(complete response (CR), partial response (PR), or stable disease (SD) divided by the total number
of evaluable patients. Descriptive analyses were performed to assess outcomes and demographic
characteristics. Freeman-Tukey double arcsine transformation of proportions was applied before
pooling these values and results were back transformed. A random effects model was used for all
pooled proportions. Forest plots were generated to show the prevalence of each study and the overall
pooled prevalence and I2 statistics were calculated. R software version 3.6.1 (package meta) was used
to perform meta-analyses.
3. Results
3.1. Literature Search Results
A flow diagram of the literature search, review and selection process is illustrated in Figure 1.
In total, the literature search yielded 10,675 individual records, after removal of duplicate records.
Screening of the titles and abstracts of these records resulted in 206 records eligible for full-text
assessment. Finally, 118 records were excluded after reading the full text, resulting in 88 eligible
publications for this review.
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3.2. Overview of the Studies
For glioblastoma, a total of 8 studies were included in this systematic review, including two phase
I trials [17,18], two phase II trials [19,20] and four retrospective analyses [21–24] (Table 1). In two
studies, pembrolizumab was administered in patients with recurrent glioblastoma every three weeks
(Q3W) in varying doses [19,22]. Three studies used nivolumab, administered most frequently in
a dose of 3 mg/kg every two weeks (Q2W) [17,23,24]. Ipilimumab was only used in combination
with bevacizumab [21] or nivolumab [17]. Lastly, one study used the PD-L1 inhibitor atezolizumab,
administered 1200 mg Q3W [18].
For brain metastases, 40 studies assessed the efficacy of ICI without RT [25–64] and 40 studies
explored the combination of ICI and RT (Table 2; Tables S2–S4). The 41 studies with ICI in BMs
include three phase III trials, eleven phase II trials, ten Extended Access Program (EAP) studies and 17
retrospective analyses. Aside from one phase I trial, all of the other studies with ICI and RT in BMs
were retrospective analyses with a highly heterogeneous study design. Therefore, the outcomes of
studies with ICI and RT are reported separately in the supplementary data (Tables S3 and S4). The most
common tumor types in all studies of ICI with or without RT were melanoma and NSCLC.
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Table 1. Primary outcomes of clinical studies with immune checkpoint inhibitors in patients with glioblastoma.
Author Study Design Tumor Type Setting Agent No. of Patients ORR PFS OS
% Months Months
Carter (2016) [21] Retrospective Glioblastoma Recurrent IPI + BEV 16 31.0 N.A. N.A.
Blumenthal (2016) [22] Retrospective Glioma Recurrent PEMBRO 17 (10 GBM) 0.0 N.A. 2.6 [range 0.4–11.6]
Chamberlain (2017) [23] Retrospective Glioblastoma Recurrent NIVO 16 0.0 2.0 (95% CI 1.3–2.7) 3.5 (95% CI 2.8–4.2)
Omuro (2018) Cohort A [17] I Glioblastoma Recurrent NIVO 10 11.0 1.9 (95% CI 1.3–4.6) 10.4 (95% CI 4.1–22.8)
Omuro (2018) Cohort B I Glioblastoma Recurrent NIVO + IPI 10 0.0 1.5 (95% CI 0.5–2.8) 9.2 (95% CI 3.9–12.7)
Omuro (2018) Cohort C I Glioblastoma Recurrent NIVO + IPI 20 10.0 2.1 (95% CI 1.4–2.8) 7.3 (95% CI 4.7–12.9)
Mantica (2018) [24] Retrospective Glioblastoma Recurrent NIVO (+ BEV) 37 0.0 4.6 [range 0.5–15.0] 6.5 [range 0.8–19.5]
Lukas (2018) [18] I Glioblastoma Recurrent ATEZO 16 6.0 1.2 [range 0.7–10.7] 4.2 [range 1.2–18.8+]
Cloughesy (2019) Cohort A [19] II Glioblastoma Recurrent PEMBRO 16 N.A. 3.3 13.7
Cloughesy (2019) Cohort B [19] II Glioblastoma Recurrent PEMBRO 16 N.A. 2.4 7.5
Schalper (2019) [20] II Glioblastoma Newly diagnosed and Recurrent NIVO 29 N.A. 4.1 (95% CI 2.8–5.5) 7.3 (95% CI 5.4–7.9)
ATEZO Atezolizumab; BEV Bevacizumab; ICI Immune checkpoint inhibitor; IPI Ipilimumab; N.A. Not available; NIVO Nivolumab; PEMBRO Pembrolizumab.
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Table 2. Primary outcomes of clinical studies with immune checkpoint inhibitors in patients with brain metastases.
Author Study Design Tumor Type Agent No. of Patients ORR PFS OS
% Months Months
Altomonte (2013) [25] EAP (Retrospective) Melanoma IPI 11 0 3.0 (95% CI 2.4–3.6) 4.0 (95% CI 2.4–5.6)
Berrocal (2014) [26] EAP (Retrospective) Melanoma IPI 29 10.8 N.A. 3.9 (95% CI 1.1–6.8)
Chasset (2015) [28] EAP (Retrospective) Melanoma IPI 23 17 N.A. 7.0 (95% CI 4.0–12.0)
Di Giacomo (2012)(2014) [30,31] II Melanoma IPI + Fotemustine 20 40.0 3.0 † (95% CI 2.9–3.1) 12.7 (95% CI 2.7–22.7)
Goldberg (2016) [36] II Melanoma PEMBRO 18 22.0 * (95% CI 7.0–48.0) N.A. N.R.
González-Cao (2017) [37] EAP (Retrospective) Melanoma PEMBRO 10 40.0 * N.A. N.A.
Kluger (2019) [38] II Melanoma PEMBRO 23 26.0 * (95% CI 10.0–48.0) 2.0 (95% CI, 2.0–N.R.) 17.0 (95% CI 10.0–N.R.)
Konstantinou (2014) [39] EAP (Retrospective) Melanoma IPI 38 5.3 * N.A. 3.3
Long (2018) Cohort A [40] II Melanoma NIVO + IPI 35 46.0 * (95% CI 29.0–63.0) N.R. † (95% CI 2.9–N.R) N.R. (95% CI 8.5–N.R.)
Long (2018) Cohort B [40] II Melanoma NIVO 25 20.0 * (95% CI 7.0–41.0) 2.5 † (95% CI 1.7–2.8) 18.5 (95% CI 6.9–N.R.)
Long (2018) Cohort C [40] II Melanoma NIVO 16 6.0 * (95% CI 0.0–30.0) 2.3 † (95% CI 1.4–4.3) 5.1 (95% CI 1.8–N.R.)
Margolin (2012) Cohort A [41] II Melanoma IPI 51 16.0 * (95% CI 7.0–29.0) 1.5 † (95% CI 1.2–2.5) 7.0 (95% CI 4.1–10.8)
Margolin (2012) Cohort B [41] II Melanoma IPI 21 5.0 * (95% CI 0.1–24.0) 1.2 † (95% CI 1.2–1.3) 3.7 (95% CI 1.6–7.3)
Parakh (2017) [43] Retrospective Melanoma NIVO or PEMBRO 66 21.0 * 5.3 † (95% CI 3.3–8.2) 9.9 (95% CI 6.9–17.7)
Parakh (2019) [42] Retrospective Melanoma NIVO + IPI 11 18.0 * 2.9 (95% CI 0.6–7.1) 17.4 (95% CI 7.1–N.R.)
Queirolo (2014) [44] EAP (Retrospective) Melanoma IPI 145 12.0 3.1 (95% CI 2.7–3.5) 4.3 (95% CI 3.4–5.2)
Tawbi (2018) [47] II Melanoma NIVO + IPI 94 55.0 * (95% CI 45–66) N.R. N.R.
Weber (2011) [46] II Melanoma IPI (+ Budesonide) 12 16.7 N.A. 14.0
Bjørnhart (2019) [27] Retrospective NSCLC NIVO or PEMBRO 21 4.8 * 4.2 (95%CI 2.5–5.9) 8.2 (95% CI 1.0–15.5)
Crinò (2019) [29] EAP NSCLC NIVO 409 17.0 3.0 (95% CI 2.7–3.3) 8.6 (95% CI 6.4–10.8)
Dumenil (2018) [32] Retrospective NSCLC NIVO 10 0 N.A. 3.1
Garde-Noguera (2018) [34] Retrospective NSCLC NIVO 38 17.2 1.6 3.1
Gauvain (2018) [35] Retrospective NSCLC NIVO 30 9.0 * (95% CI 3.0–23.0) 3.9 † (95% CI 2.8–11.1) N.R.
Goldberg (2016) [36] II NSCLC PEMBRO 18 33.0 * (95% CI 14.0–59.0) N.A. 7.7 (95% CI 3.5–N.R.)
Spigel (2018) Cohort 3 [60] II NSCLC ATEZO 13 23.0 (95% CI 5.0–54.0) 2.5 6.8 (95% CI 3.2–19.5)
Flippot (2019) Cohort A [33] II RCC NIVO 39 11.8 * (95% CI 3.3–27.5) 2.7 † (95% CI 2.3–4.6) N.A.
Flippot (2019) Cohort B [33] II RCC NIVO + Local Tx 34 N.A. 4.8 † (95% CI 3.0–8.0) N.A.
Sternberg (2019) [45] III UTC ATEZO 14 0 (95% CI 0–23.0) 2.0 (95% CI 1.5–2.3) 3.7 (95% CI 1.5–7.0)
* Intracranial ORR; † Intracranial PFS. EAP Expanded access program; ICI Immune checkpoint inhibitor; IPI Ipilimumab; N.A. Not available; NIVO Nivolumab; N.R. Not reached;
PEMBRO Pembrolizumab; UTC Urinary Tract Cancer.
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3.3. Immune Checkpoint Inhibitors in Glioblastoma
The efficacy and survival outcomes of all studies are summarized in Table 1. The median survival
of the patients with glioblastoma treated with ICI in all studies is 7.3 months. Furthermore, the median
PFS reported in these studies was 2.1 months (Table 3).
Table 3. Median survival outcomes of immune checkpoint inhibitors in patients with glioblastoma or
brain metastases.
Variable Glioblastoma Brain Metastases
Melanoma NSCLC All
IPI NIVO PEMBRO IPI + NIVO PEMBRO NIVO ATEZO All
Median
Intracranial PFS 2.1 mo 1.2–3.0 mo 2.3–2.5 mo N.A. N.A. N.A. 3.9 mo N.A. 2.7 mo
Median PFS - 3.0–3.1 mo N.A. 2.0–5.2 mo 2.9 mo N.A. 1.6–3.0 mo 2.5 mo 3.0 mo
Median OS 7.3 mo 3.3–14.0 mo 5.1–18.5 mo 17.0–20.4 mo 17.4 mo 7.7 mo 2.8–9.0 mo 6.8 mo 8.0 mo
ATEZO: Atezolizumab; PFS: Progression-free survival; OS: Overall survival; IPI: Ipilimumab; NIVO: Nivolumab;
PEMBRO: Pembrolizumab. N.A.: Not available; mo: Months.
Overall, objective responses to ICI in recurrent glioblastoma were seen in three studies [17,18,21].
In the retrospective analysis of Carter et al., an ORR of 31% was seen in patients with recurrent
glioblastoma, who were treated with ipilimumab, 3 mg/kg Q3W, combined with bevacizumab [21].
In the phase I trial reported by Omuro et al., in 2018, objective responses were seen in two of the
three treatment arms. The ORR in the treatment arms with nivolumab monotherapy (3 mg/kg
Q2W) and nivolumab (3 mg/kg Q2W) combined with ipilimumab (1 mg/kg) were 11% and 10%,
respectively [17]. Lastly, the phase I study of Lukas et al., with atezolizumab (1200 mg Q3W) in
16 patients with glioblastoma showed an ORR of 6.0% [18]. Three patients with IDH1-mutant tumors
had better PFS (5.5 months vs. 1.2 months) and a trend towards a longer OS (16.0 months vs.
2.7 months) than patients with IDH1-wild-type tumors. Interestingly, neoadjuvant PD-1 blockade
with pembrolizumab in patients with recurrent, surgically resectable glioblastoma demonstrated a
significant improvement in OS compared to adjuvant PD-1 blockade alone. Furthermore, neoadjuvant
PD-1 blockade was associated with upregulation of T cell and interferon-γ-related gene expression,
but downregulation of genes related to the cell-cycle in the tumor [19]. Similar intratumoral and
systemic immune changes were found in a single-arm, phase II trial with neoadjuvant nivolumab
in surgically resectable, newly diagnosed or recurrent glioblastoma [20]. Currently, three important
studies with nivolumab in newly-diagnosed and recurrent glioblastoma are awaiting final publication,
but have reported preliminary, disappointing primary outcomes (Table 4). First, in the randomized,
open-label, phase III CheckMate-143 trial (NCT02017717), nivolumab monotherapy did not significantly
improve overall survival in patients with recurrent glioblastoma, compared to treatment with
bevacizumab [65]. Furthermore, the combination of nivolumab with radiotherapy in the CheckMate-498
trial (NCT02617589) also failed to significantly prolong the overall survival of patients with newly
diagnosed O6-methylguanine-DNA methyltransferase (MGMT)-unmethylated glioblastoma, compared
to combined treatment with temozolomide and radiotherapy. Lastly, the addition of nivolumab to
the first-line treatment with temozolomide and radiotherapy in newly diagnosed MGMT-methylated
glioblastoma patients (CheckMate-548; NCT02667587), failed to meet one of its primary endpoints, i.e.,
PFS, and is currently awaiting the overall survival data.
3.4. Outcomes of Immune Checkpoint Inhibitors in Brain Metastases
An overview of the efficacy and survival outcomes is provided in Table 2 and Supplementary
Table S2 for all studies with checkpoint inhibitors in brain metastases, and Table S3 for the studies that
combined checkpoint inhibitors with radiotherapy. The median intracranial PFS for patients with brain
metastases treated with ICI in these studies is 2.7 months, compared to an overall PFS of 3.0 months.
The median survival of these patients reported in the studies was 8.0 months (Table 3).
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Table 4. Important studies with immune checkpoint inhibitors in newly-diagnosed and recurrent
glioblastoma awaiting publication.
NCT Number Official Trial Name Phase Primary Endpoint Endpoint Status
NCT02017717
A Study of the Effectiveness and Safety of Nivolumab Compared
to Bevacizumab and of Nivolumab With or Without Ipilimumab
in Glioblastoma Patients (CheckMate-143)
III Overall survival Endpoint not met
NCT02617589
An Investigational Immuno-therapy Study of Nivolumab
Compared to Temozolomide, Each Given With Radiation Therapy,
for Newly-diagnosed Patients With Glioblastoma (GBM, a
Malignant Brain Cancer) (CheckMate-498)
III Overall survival Endpoint not met
NCT02667587
An Investigational Immuno-therapy Study of Temozolomide Plus
Radiation Therapy With Nivolumab or Placebo, for Newly
Diagnosed Patients With Glioblastoma (GBM, a Malignant Brain
Cancer) (CheckMate-548)
III Progression-free survivalOverall survival
Endpoint not met
Endpoint in progress
In patients with melanoma BMs, 13 studies explored the efficacy of ipilimumab
monotherapy. The pooled intracranial objective response rate (iORR) and ORR for ipilimumab
are 9.0% (95% CI 3.0–17; I2 = 29%) and 14.0% (95% CI 6.0–24.0 I2 = 57%), respectively
(Figure 2) [25,26,28,30,31,39,41,44,46,48–50,55]. Furthermore, the median survival in these studies
ranged from 3.3 to 14.0 months and the intracranial PFS ranged from 1.2 to 3.0 months.
For pembrolizumab monotherapy, four studies conducted in patients with melanoma BMs reported an
intracranial ORR 22.0–40.0% (Figure S1) [36–38,51]. The median PFS and OS of these patients were 2.0
to 5.2 months and 17.0–20.4 months, respectively. Long et al., and Larkin et al., explored the efficacy
of nivolumab monotherapy in melanoma BMs [57]. The median survival and PFS for patients with
BMs in these studies ranged from 5.1 to 18.5 months and 2.3 to 2.5 months, respectively. Furthermore,
the reported intracranial ORR was 6.0–20.0%. Lastly, three studies explored the efficacy of ipilimumab
combined with nivolumab [40,42,47]. In two of the three studies, the median OS and PFS were not
reached. However, Parakh et al., reported a median OS of 17.4 months (95% CI 7.1–N.R.) and a PFS
of 2.9 months (95% CI 0.6–7.1) [42]. Interestingly, the intracranial ORR in these three studies were
18.0–55.0% (Figure S2).Cancers 2020, 12, 586 9 of 16 
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compared to 4.8 months (95% CI 3.0–8.0) for patients with RCC BMs, who were treated with 
nivolumab and local therapy. The median PFS of the patients in the study of De Giorgi et al. was 4.4 
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patients with BMs from urothelial and non-urothelial urinary tract carcinoma (UTC), treated with 
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Figure 2. Pooled analysis for intracranial OR d overall O R (B) of ipili umab in patients with
melanoma brain metastases.
In NSCLC brain metastases, eight studies r rted efficacy and survival outcomes of tr atment
with ICI. In six studies with nivolu ab onotherapy, the patients had a median survival of 3.1 to
9.0 months [29,32,34,35,56,62]. Furthermore, median PFS ranged from 1.6 to 3.0 months. The pooled
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ORR in these studies was 14% (95% CI 8.0–23.0; I2 = 29%) (Figure S3). Subsequently, Goldberg et al.,
reported an intracranial ORR of 33.0% (95% CI 14.0–59.0) in patients with NSCLC BMs treated with
pembrolizumab [36]. The median survival of these patients was 7.7 months (95% CI 3.5–N.R.). Lastly,
Spigel et al., explored the efficacy of atezoluzimab in a cohort of patients with NSCLC and treated
BMs [60]. The ORR in this cohort was 23.0% (95% CI 5.0–54.0) and patients had a PFS and OS of
2.5 months and 6.8 months (95% CI 3.2–19.5), respectively.
In other solid malignancies, only four studies reported efficacy and/or survival outcomes of
patients with brain metastases, who were treated with ICI. First, in the phase II trial of Gadgeel et
al., patients with small cell lung cancer (SCLC) were treated with pembrolizumab, 200 mg Q3W [54].
The median survival of these patients was 9.6 months (95% CI 7.0–12.0) and patients had a median PFS
of 1.4 months (95% CI 1.2–2.8). Second, Flippot et al., and De Giorgi et al., reported an intracranial
ORR of 11.8% and an ORR of 18.8%, respectively, in patients with renal cell cancer (RCC), who were
treated with nivolumab, 3 mg/kg Q2W [33,52]. The median survival was not reached or available in
these studies. However, Flippot et al., reported a median intracranial PFS 2.7 months (95% CI 2.3–4.6),
compared to 4.8 months (95% CI 3.0–8.0) for patients with RCC BMs, who were treated with nivolumab
and local therapy. The median PFS of the patients in the study of De Giorgi et al., was 4.4 months (95%
CI 3.7–6.2). Lastly, the study of Sternberg et al., observed no objective responses in patients with BMs
from urothelial and non-urothelial urinary tract carcinoma (UTC), treated with atezolizumab 1200 mg
Q3W [45]. The median PFS and OS of the patients in this study were 2.0 months (95% CI 1.5–2.3) and
3.7 months (95% CI 1.5–7.0), respectively.
4. Discussion
In this systematic review, we examined the efficacy and survival outcomes of checkpoint inhibitors
in patients with glioblastoma and brain metastases.
For glioblastoma, we found that the vast majority of the studies with checkpoint inhibitors in
recurrent glioblastoma showed minimal clinical activity. Furthermore, although currently awaiting final
publication, preliminary results of the three landmark CheckMate studies with nivolumab have failed
to meet their primary endpoint [65]. Based on these results, the use of immune checkpoint inhibitors is
not applicable for patients with glioblastoma. Aside from the blood–brain barrier, which affects the
drug delivery in brain tumors, it is suggested that several factors play an important role in the limited
efficacy of checkpoint inhibitors in glioblastoma, compared to brain metastases of solid tumors. First,
glioblastoma generally exhibits a relatively low mutational load compared to other solid tumors (i.e.,
melanoma and NSCLC), with an exemption of the infrequent cases of glioblastoma in which there
is a defective mismatch repair system, resulting in a higher mutational load [66,67]. Furthermore,
in contrast to melanoma and NSCLC brain metastases and their primary tumors, the gene expression
signature of glioblastoma induces a highly immunosuppressive microenvironment, including a
relatively low neoantigen burden and low number of tumor-infiltrating lymphocytes (TILs) [68,69].
Therefore, to overcome these difficulties, a multimodal, molecular approach may be necessary to
increase the immune microenvironment and anti-tumor response in a selected subgroup of patients
with glioblastoma.
Intracranial responses have been reported in studies with melanoma and NSCLC brain metastases.
While multiple studies in melanoma brain metastases report intracranial objective responses with
anti-PD-1 and/or anti-CTLA-4 immunotherapy, the evidence in NSCLSC BMs is limited to anti-PD-1
immunotherapy (i.e., predominantly nivolumab). Despite the encouraging evidence to presume that
ICI can demonstrate intracranial objective responses in patients with brain metastases, the survival
outcomes for these patients remain poor. Patients with brain metastases in the reviewed literature had
a median intracranial and total PFS of 2.7 and 3.0 months, respectively. Furthermore, the reported
median OS in all the reviewed studies was only 8.0 months. Several factors might play a role for the
limited number of responses and poor PFS reported in patients with melanoma and NSCLC brain
metastases. First, as with glioblastoma, the number of TILs in the microenvironment of brain metastases
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is highly heterogeneous and differs between patients [70]. Second, the density of these TILs seems
to be significantly correlated with the amount of peritumoral brain edema and survival outcome in
patients with brain metastases [71]. Lastly, it is hypothesized that the use of corticosteroids, which are
frequently administered in patients with brain metastases and glioblastoma for the management of
cerebral edema, may restrain a tumor-specific immune response to checkpoint inhibition by impairing
T lymphocyte activation [41,72]. In particular, baseline use of steroids prior to the initiation of ICI
seems to be correlated with a decreased ORR, PFS and OS, while the use of corticosteroid after initiation
of ICI is not [73,74].
Currently, only a small subset of patients with glioblastoma or BMs with microsatellite instable or
mismatch repair deficient tumors, resulting in a higher tumor mutational burden, may benefit from
ICI. Therefore, new treatment strategies are necessary to increase the response to ICI in patients with
glioblastoma or BMs. First, the use of ICI in combination or in sequence with radiotherapy has mostly
been explored in retrospective studies. Unfortunately, in the absence of randomized, prospective data,
it is difficult to draw any conclusion about the optimal timing and sequencing of radiotherapy with
ICI from these studies. Second, a potential way to overcome the highly immunosuppressive tumor
microenvironment and low number of TILs is by inhibiting histone deacetylases (HDAC). Inhibition of
HDACs lead to increased histone acetylation, resulting in increased gene expression [75]. Recently,
both the HDAC inhibitor mocetinostat and inhibition of HDAC6 independently demonstrated a
synergistic effect in combination with ICI, resulting in increased anti-tumor activity in NSCLC and
ovarian cancer cell lines by increasing tumor antigen presentation and decreasing immune suppressive
cell types [76,77]. Furthermore, in a phase I study, an adenovirus vector encoding the IL-12 gene was
injected during surgery in the resection cavity walls of patients with recurrent high-grade glioma,
followed by post-operative treatment with the oral activator for human IL-12, veledimex. In the
tissue of five patients that received a re-resection, increased tumor-infiltrating lymphocytes producing
interferon-γ and PD-1 were seen, supporting the hypothesis of an immunological antitumor effect of
human IL-12 [78]. Collectively, these data suggest that a multimodal approach is necessary to increase
the activation of the immune system in the tumor microenvironment and anti-tumor response to ICI in
patients with glioblastoma or BMs.
A few important limitations should be considered in the interpretation of the results reported in
this systematic review. First, given the limited number of available randomized controlled trials and
the retrospective nature of several included studies, the results in these studies are subjected to a certain
degree of selection bias and therefore the real-world data may be worse. Subsequently, a considerable
heterogeneity exists in the reported data of the studies, most likely due to the differences in study
design, number of patients, study treatment and disease evaluation. A random effects models was used
for our pooled analysis of ORR to minimize the bias in these data. Second, not every study included
in this systematic review had complete data available for all the outcomes of interest. Furthermore,
data on microsatellite stability, mismatch repair deficiency and tumor mutational burden were lacking.
Therefore, unfortunately, no conclusions can be drawn about the correlation between the genetic profile
and response to ICI. Lastly, most of the included studies predominantly focused on the use of ICI in
melanoma BMs, compared to a select number of studies in NSCLC BMs and minimal data available in
BMs of other solid tumors for which ICI are FDA-approved. Therefore, the outcomes of the studies
with ICI in NSCLC BMs should be interpreted with caution and primarily in the setting of melanoma
and NSCLC.
5. Conclusions
In conclusion, immune checkpoint inhibition, in its current state, demonstrates limited efficacy
in glioblastoma and has failed to improve the survival of these patients. Therefore, for the future
of immunotherapy in glioblastoma, research should focus on a multi-modal approach to activate
local and systemic tumor-specific immune responses in glioblastoma. In patients with melanoma
and NSCLC brain metastases, intracranial objective responses are seen with checkpoint inhibitors.
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However, due to the relatively poor overall survival, intracranial and total PFS with checkpoint
inhibitors, local and systemic personalized treatment recommendations should be discussed in a
multidisciplinary neuro-oncology tumor board. To move the field of checkpoint inhibition in brain
metastases forward, we suggest more and larger prospective randomized controlled trials for patients
with brain metastases. This must result in comprehensive evidence of the therapeutic potential of
FDA-approved immune checkpoint inhibitors in brain metastases and subsequent determination of
whether checkpoint inhibition improve quality of life and overall survival for these patients.
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